RegWardenFDA facility compliance records
Facility

Clarity Diagnostics, LLC

1 recall(s) on record — most severe on record: Class III.

Activity by year

FDA actions on record by year2018: 1 recalls; 2019: 1 inspections; 2022: 1 inspections2017120181201920202021120222023202420252026
  • Recalls (1)
  • Inspections (2)

Devices registered here (1)

  • Visual, Pregnancy Hcg, Prescription Use
    Product code JHI (opens in a new tab) · Class II · Clinical Chemistry · 21 CFR 862.1155

Recalls & enforcement

  • Class IIITerminated2018-06-22
    Clarity Diagnostics LLC discovered specific lots of Clarity 10SG Strips are not compatible for use in the Clarity Urocheck 120 Urine Analyzers, due to lack of Canister Code Bar Code Label.

FDA inspections (2)

  • NAI2022-04-06
    No Action Indicated · Compliance: Devices; Postmarket Assurance: Devices
  • VAI2019-05-08
    Voluntary Action Indicated · Compliance: Devices; Postmarket Assurance: Devices · citations posted

Source: U.S. FDA Inspections Dashboard (opens in a new tab) (device inspection classifications, 2016–present). Data as of 2026-10-06. The dashboard profile can take several seconds to load.

Related

Source: U.S. FDA via openFDA (opens in a new tab) (device registration & enforcement). Data as of 2026-10-06. Verify this facility record at FDA → (opens in a new tab)

Cite this record

RegWarden. “Clarity Diagnostics, LLC (FEI 3004043187) — FDA facility record.” Compiled from U.S. FDA public records (openFDA; FDA Data Dashboard). Data as of 2026-10-06. https://regwarden.com/facility/3004043187-clarity-diagnostics-llc/

Not open yet

Alerts for Clarity Diagnostics, LLC

Watchlist alerts will email you when FDA publishes a new recall, inspection classification, or warning letter for a facility you follow. They aren't open to the public yet — leave your email and we'll tell you when they are.

Planned

Want a one-page facility brief?

A single-page summary of this facility's registration and recall history for diligence. Not selling it yet — register interest and we'll follow up.